Back to search
FDAFDA · Food and drugs·Recall number D-0165-2021

Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40

Published December 23, 2020 · Recall initiated: December 14, 2020

Summary

FDA records drug Class II recall D-0165-2021, published December 23, 2020 and initiated December 14, 2020. Recalling firm: CIPLA; Status: Terminated; Reported quantity: 2151 vials; Lot: Lot #: 7S10182A, Ex 9/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations: Vials may not be sealed correctly affecting sterility.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
CIPLA
Distributor
USA Nationwide
Lot
Lot #: 7S10182A, Ex 9/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40 recalled?

Yes. FDA published recall D-0165-2021 on December 23, 2020. Reported hazard: cGMP deviations: Vials may not be sealed correctly affecting sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit